Mural Oncology plc (MURA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mural Oncology plc (MURA) has a cash flow conversion efficiency ratio of -0.335x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.48 Million) by net assets ($55.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Mural Oncology plc to measure how much of total assets are equity-financed.
Mural Oncology plc - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Mural Oncology plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore how well can Mural Oncology plc service its debt to assess how comfortably operating cash covers total debt obligations.
Mural Oncology plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mural Oncology plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ihlas Gayrimenkul Proje Gelistirme ve Ticaret AS
IS:IHLGM
|
0.012x |
|
Soktas Tekstil Sanayi ve Ticaret AS
IS:SKTAS
|
0.017x |
|
Fundamental Global Inc.
NASDAQ:FGNX
|
-0.010x |
|
Metavista3D Inc.
V:DDD
|
N/A |
|
Coastal Corporation Limited
NSE:COASTCORP
|
0.022x |
|
Metalstech Ltd
AU:MTC
|
-0.074x |
|
Jack Chia Industries (Thailand) Public Company Limited
BK:JCT
|
0.022x |
|
MUI Properties Bhd
KLSE:3913
|
0.757x |
Annual Cash Flow Conversion Efficiency for Mural Oncology plc (2021–2024)
The table below shows the annual cash flow conversion efficiency of Mural Oncology plc from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see MURA company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $140.50 Million | $-128.54 Million | -0.915x | -24.26% |
| 2023-12-31 | $263.82 Million | $-194.25 Million | -0.736x | -109.46% |
| 2022-12-31 | $-21.66 Million | $-168.59 Million | 7.785x | -11.16% |
| 2021-12-31 | $-17.88 Million | $-156.67 Million | 8.763x | -- |
About Mural Oncology plc
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cut… Read more